- Report
- March 2024
- 186 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- March 2024
- 143 Pages
Global
From €2895EUR$2,999USD£2,483GBP
- Report
- May 2023
- 143 Pages
Global
From €2412EUR$2,499USD£2,069GBP
- Report
- February 2024
- 111 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- April 2024
- 262 Pages
Global
From €7673EUR$7,950USD£6,582GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Report
- November 2023
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- November 2023
- 250 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- August 2023
- 203 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- March 2024
- 224 Pages
Global
€4821EUR$4,995USD£4,136GBP
- Report
- August 2023
- 150 Pages
United States
From €3619EUR$3,750USD£3,105GBP
- Report
- August 2023
- 113 Pages
North America
From €1448EUR$1,500USD£1,242GBP
- Report
- May 2018
- 170 Pages
Global
From €2316EUR$2,400USD£1,987GBP
- Report
- February 2023
- 188 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- February 2023
- 94 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- September 2022
- 30 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- April 2024
- 180 Pages
From €4729EUR$4,900USD£4,057GBP
Hydroxycarbamide is a drug used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by inhibiting the growth of cancer cells. It is also used to treat polycythemia vera, a rare blood disorder. Hydroxycarbamide is usually taken orally in tablet form, and is usually taken once or twice a day. It is also available in an injectable form. Common side effects of hydroxycarbamide include nausea, vomiting, diarrhea, and hair loss.
Hydroxycarbamide is a relatively new drug, and is still in the process of being approved by regulatory bodies in different countries. It is currently approved in the United States, Canada, and the European Union. It is also approved in some other countries, such as Australia, New Zealand, and South Africa.
Hydroxycarbamide is marketed by several pharmaceutical companies, including Novartis, Bristol-Myers Squibb, and Pfizer. Other companies that market hydroxycarbamide include Cipla, Teva Pharmaceuticals, and Mylan. Show Less Read more